Inventor · disambiguated record
Yen Lin Chia
Also filed as: CHIA YEN LIN
2 granted patents·7 pending applications·5 citations·filing 2013–2024
53Inventor score
Top patents by PatentIndex Score
9 records- 0186US12060429B2Method of treating type 1 interferon (IFN)-mediated disease using a subcutaneous dosing regimen comprising anifrolumabASTRAZENECA AB·Filed 2023·Granted Aug 13, 2024·2 cites·10 claims
- 0274US10132810B2Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitorNEKTAR THERAPEUTICS·Filed 2013·Granted Nov 20, 2018·3 cites·17 claims
- 0373US2024400699A1Anti-ifnar1 dosing regime for subcutaneous injectionASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 0472US2024360231A1DoseASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 0565US2022340669A1DoseASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 0661US2025002590A1Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumabASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 0761US2022348669A1Treatment of lupus nephritisASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 0857US2025002589A1Treatment of cutaneous lupus erythematousASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 0956US2019049450A1Method for Assessing and Predicting Efficacy of Breast Cancer Treatment with a Long-Acting Topoisomerase I InhibitorNEKTAR THERAPEUTICS·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yen Lin Chia files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →